Scarica l'app Stockscreener
11.45
18.16%
1.76
Pre-mercato:
11.40
-0.05
-0.44%
Climb Bio Inc Borsa (CLYM) Ultime notizie
Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE - Yahoo Finance
Climb Bio Secures 110 Million Dollars Through Private Stock Placement - HarianBasis.co
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing - Insider Monkey
Climb Bio reports B-cell depletion data for budoprutug trial - Investing.com UK
Drug shot matched IV B-cell depletion in Climb Bio study; June data next - Stock Titan
Climb Bio Highlights Budoprutug Progress at R&D Spotlight - TipRanks
Climb Bio : Budoprutug and the CD19 Opportunity - marketscreener.com
Climb Bio shares positive topline SC budoprutug data, ITP readout June, pMN & SLE readouts Q4 2026 - TradingView
Climb Bio (CLYM) outlines budoprutug CD19 data, 2026 trial readouts and cash runway - Stock Titan
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting - GlobeNewswire
Chardan initiates Climb Bio stock with buy on autoimmune pipeline By Investing.com - Investing.com India
5 Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Analysts Raise Price Targets for Climb Bio Following Clinical Updates - HarianBasis.co
Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026 - Insider Monkey
CLYM Stock Price, Quote & Chart | CLIMB BIO INC (NASDAQ:CLYM) - ChartMill
RA Capital funds receive Climb Bio (CLYM) pre-funded warrants in new grant - Stock Titan
RA Capital lifts Climb Bio (CLYM) stake with $20M PIPE warrants - Stock Titan
Climb Bio (CLYM) Receives FDA Fast Track Designation for Budoprutug in Rare Kidney Disease - Insider Monkey
5 Best Performing Small Cap Stocks So Far in 2026 - Insider Monkey
10 Tiny Stocks That Are On Fire Right Now - Insider Monkey
Climb Bio raises $110 million in private placement - Investing.com UK
Climb Bio raises $110 million in private placement By Investing.com - Investing.com Australia
Budoprutug potential in CD19 antibody therapy spotlighted by Climb Bio, Inc. - Traders Union
Climb Bio raises $110M in private placement; shares up - MSN
Climb Bio, Inc. announced that it expects to receive $110.076289 million in funding from a group of investors - marketscreener.com
Climb Bio Raises $110 Million in Private Placement - TipRanks
Climb Bio (CLYM) secures $110M private placement with institutional investors - Stock Titan
Climb Bio, Inc. Announces $110.0 Million Private Placement - markets.businessinsider.com
Climb Bio, Inc. Announces $110 Million Private Placement of Common Stock and Pre-Funded Warrants - Quiver Quantitative
CLIMB BIO INCPRIVATE PLACEMENT EXPECTED TO CLOSE ON OR ABOUT APRIL 29, 2026 - Moomoo
Institutional investors commit $110M in Climb Bio share sale - Stock Titan
Climb Bio, Inc. joins The Future of Clinical Trial Design in IgA nephropathy - Traders Union
Executive pay and governance moves at Climb Bio (NASDAQ: CLYM) - Stock Titan
Mizuho initiates coverage of Climb Bio (CLYM) with outperform recommendation - MSN
CLYM (Climb Bio Inc.) rises 3.85 percent even as fourth quarter 2025 per share earnings miss analyst estimates.Hedge Fund Inspired Picks - UBND thành phố Hải Phòng
BLTE (Belite Bio Inc American Depositary Shares) posts wider Q4 2025 loss than estimates, shares climb amid optimistic investor sentiment.Cost Structure - Xã Thanh Hà
Climb Bio, Inc. $CLYM Shares Sold by JPMorgan Chase & Co. - MarketBeat
Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Oppenheimer Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $18 - Moomoo
Climb Bio Sees Upgraded Outlook on Strong IgAN Drug Development Pipeline, Oppenheimer Says - marketscreener.com
Oppenheimer Raises Climb Bio (NASDAQ:CLYM) Price Target to $18.00 - MarketBeat
Oppenheimer Adjusts Price Target on Climb Bio to $18 From $10, Maintains Outperform Rating - marketscreener.com
Oppenheimer raises Climb Bio stock price target on clinical data By Investing.com - Investing.com Canada
FDA Grants Fast Track Designation to Climb Bio Kidney Drug - HarianBasis.co
FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a Must-Buy Small Cap Stock? - Insider Monkey
8 Must-Buy Small Cap Stocks to Buy - Insider Monkey
Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway (CLYM) - Seeking Alpha
Climb Bio, Inc. backs scientific collaboration on innovative trial design in nephrology - Traders Union
Climb Bio (NASDAQ:CLYM) Upgraded to "Strong-Buy" at Mizuho - MarketBeat
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):